Novartis' heart failure drug serelaxin meets targets – PMLiVE
Novartis' heart failure drug serelaxin meets targetsPMLiVEA phase III trial of Novartis' serelaxin has met its primary target of reducing shortness of breath in acute heart failure patients, although there is some debate about the clinical sign…